Jagsonpal completes 85% acquisition of Aequitas Healthcare

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹224.51

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%-1.3% vs market

Pharmaceuticals peers, median of 167sector+0.8%-1.5% vs sector

On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.7+0.6-1.3+0.8-1.5

Next day

-1.1+0.9-2.1+0.8-1.9

-2.4-0.2-2.2-0.5-1.9

-2.3-0.9-1.4-1.6-0.7

-1.7-0.5-1.2-1.5-0.2

+2.4+0.8+1.6-0.7+3.1

+2.4-0.0+2.5-0.9+3.4

15d

+4.2+3.9+0.3+0.6+3.7

+3.7+4.8-1.2-1.1+4.8

+0.9+5.1-4.3+2.2-1.4

-2.7-1.6-1.0-4.6+1.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jagsonpal Pharmaceuticals has completed acquiring an 85% equity stake in Aequitas Healthcare Private Limited, making it an 85% subsidiary. The deal was first announced on June 29, 2026, with updates on July 7 and July 8, 2026. Deal value and financial terms were not disclosed in this filing.

Likely market impact

Grows the company's healthcare business via a majority subsidiary. Deal valuation and earnings impact remain undisclosed in this update.